hudson: durvalumab combination therapies to overcome pd-l1 blockade resistance in advanced nsclc
Published 2 years ago • 331 plays • Length 2:53Download video MP4
Download video MP3
Similar videos
-
11:11
extending durvalumab maintenance to special populations
-
6:35
no benefit for adjuvant durvalumab in completely resected nsclc
-
1:07
combining 1l chemo-immunotherapy with oleclumab in patients with advanced tnbc
-
2:03
tremelimumab and durvalumab therapy in lung cancer
-
6:22
refining which patients benefit from consolidation durvalumab for stage iii unresectable nsclc
-
1:29
how can durvalumab be used in nsclc?
-
2:10
poseidon: 4 year follow up of durvalumab and tremelimumab in nsclc
-
1:01:11
advances in immunotherapy in ovarian cancer
-
4:27
understanding immunotherapy for nsclc with pd-1 and pd-l1 biomarkers
-
1:12:46
immunotherapy treatment and survivorship: precision medicine in action
-
0:43
double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in nsclc
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
![[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital](https://i.ytimg.com/vi/EwpYIgllxqY/mqdefault.jpg)
3:53
[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital
-
11:30
durvalumab following radiotherapy in patients with unresectable, stage 3 nsclc ineligible for ch...
-
2:11
phase ii trial of platinum-etoposide chemotherapy & durvalumab with sbrt for small cell lung cancer
-
1:26
the challenge of treatment resistance in patients with advanced egfr-mutated nsclc
-
1:00
combining sabr and immunotherapies for nsclc
-
6:48
durvalumab improves pfs in stage iii lung cancer
-
1:43
treating tumors with synb1891 to overcome anti-pd1 resistance
-
7:47
combination tremelimumab and durvalumab in hcc
-
3:25
impact of radiation dose to immune cells in unresectable or stage iii nsclc in the durvalumab era
-
6:47
case 1: immunotherapy in locally advanced nsclc